Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $2.41 in the prior trading day, AbCellera Biologics Inc (NASDAQ: ABCL) closed at $2.19, down -9.13%. In other words, the price has decreased by -$9.13 from its previous closing price. On the day, 4.15 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ABCL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.81 and its Current Ratio is at 9.81. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 22, 2024, The Benchmark Company Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $9.
On December 05, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $6.KeyBanc Capital Markets initiated its Overweight rating on December 05, 2023, with a $6 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 22.64 while its Price-to-Book (P/B) ratio in mrq is 0.61.
Stock Price History:
Over the past 52 weeks, ABCL has reached a high of $4.34, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is -9.19%, while the 200-Day Moving Average is calculated to be -20.12%.
Shares Statistics:
A total of 295.76M shares are outstanding, with a floating share count of 223.58M. Insiders hold about 24.97% of the company’s shares, while institutions hold 36.87% stake in the company.
